Overview

Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

200 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive ergometrine 0.5mg (methergin®, Novartis, Switzerland).

Phase:

Phase 3

Details

Lead Sponsor:

Cairo University

Treatments:

Carbetocin
Ergonovine
Oxytocin